IGKC
Immunoglobulin kappa constant
Protein Summary
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affin ...more
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 0.8 | ||
PubMedID | 0.8 | ||
pathway | 0.74 | ||
drug | 0.7 | ||
cell line | 0.63 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 0 (req: < 5)
Gene RIFs: 19 (req: <= 3)
Antibodies: 0 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 0 (req: >= 5)
Gene RIFs: 19 (req: > 3)
Antibodies: 0 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 19
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0